A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine

Table 4 Observed pregabalin and duloxetine drug-drug interactions by severity and interacting drug

Severity*	Interacting drug	Number of interactions
Pregabalin
Major	naproxen	17
	Total Major for pregabalin	17
	Grand total for pregabalin	17
Duloxetine
Contraindicated	metoclopramide	11
	Total Contraindicated for duloxetine	11
Major	tramadol	35
Major	trazodone	31
Major	cyclobenzaprine	31
Major	meloxicam	29
Major	citalopram	25
Major	clopidogrel	91
Major	methadone	21
Major	fluoxetine	25
Major	ibuprofen	22
Major	escitalopram	11
Major	sertraline	32
Major	diclofenac	18
Major	paroxetine	17
Major	celecoxib	9
Major	naproxen	9
Major	venlafaxine	12
Major	nabumetone	4
Major	etodolac	3
Major	piroxicam	3
Major	lithium	4
Major	indomethacin	3
Major	cilostazol	10
Major	sulindac	6
Major	propafenone	2
	Total Major for duloxetine	453
Moderate	amitriptyline	40
Moderate	warfarin	59
Moderate	promethazine	15
Moderate	ciprofloxacin	14
Moderate	tamsulosin	25
Moderate	doxepin	8
Moderate	nortriptyline	6
Moderate	prochlorperazine	3
Moderate	enoxaparin	9
Moderate	imipramine	1
Moderate	dabigatran	1
Moderate	butalbital	4
	Total Moderate for duloxetine	185
	Grand total for duloxetine	649

*Severity category according to Micromedex 2.0 (Truven Health Analytics Inc., Greenwood Village, CO), as of May 31, 2013.

ISSN: 1472-6963